Clinical Trials Logo

Hodgkin Disease clinical trials

View clinical trials related to Hodgkin Disease.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06201507 Enrolling by invitation - Hodgkin Lymphoma Clinical Trials

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Start date: October 1, 2022
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to use modified Brentuximab Vedotin+doxorubicin+vinblastine+dacarbazine+Rituximab(BV-AVD-R) regimen in Chinese Classical Hodgkin's Lymphoma(HL) children. The main questions it aims to answer are: - [Overall Response Rate(ORR) :Complete Response(CR)+Partial Response(PR)] - [progression-free survival (PFS), event-free survival (EFS) and overall survival (OS) at 6 months and 1 year.] Participants will be given modified BV-AVD-R regimen according to rapid early responders (RER) or slow early responders (SER) after 2 cycles.

NCT ID: NCT05683704 Enrolling by invitation - Clinical trials for Recurrent/Refractory Classical Hodgkin's Lymphoma

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This study is a single arm, open, multi center phase II exploratory study. To evaluate the efficacy and safety of AK105 combined with androtinib hydrochloride capsule in patients with relapsed/refractory classical Hodgkin's lymphoma (relapse or progression after autologous stem cell transplantation, or relapse progression after autologous stem cell transplantation but ≥ 1 line systemic multi drug combination chemotherapy). After screening, the subjects met the inclusion criteria and did not meet the exclusion criteria, and then entered the treatment period. They received AK105 injection (once every three weeks, 200mg/time, intravenous infusion) combined with androtinib hydrochloride capsule (once a day, 10mg each time, and stopped for one week for two consecutive weeks). Every 21 days was a treatment cycle until disease progression/intolerance occurred or the sponsor terminated the study. Patients with complete remission (CR) continue to receive 4 cycles of treatment, and then further consolidate treatment every 9 weeks within 1 year of continuous CR, and can stop treatment after 1 year of continuous CR. At the end of the trial, the subjects who can still benefit from the study treatment as judged by the investigator will continue to be provided with the trial drug. The longest administration time of AK105 combined with androtinib hydrochloride capsules shall not exceed 2 years.

NCT ID: NCT04986189 Enrolling by invitation - Lung Cancer Clinical Trials

Lung Screening in People Cured of Hodgkin Lymphoma

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

A single site non-commercial study in which people treated for Hodgkin lymphoma survivors will be invited to have a single low dose CT of thorax for lung cancer screening